Ecuador ARCSA registro sanitario is single-IoR: the local company owns the license

Ecuador is a single-holder market for medical-device sanitary registration. Resolución ARCSA-DE-2023-033-AKRG is the rule U.S. teams keep missing: the registro sanitario has to be applied for by a locally registered Ecuadorian company, and that company becomes the sole registration holder. There is no “add three distributors later and keep the certificate in Miami.”

If your LATAM launch plan still says “Ecuador: appoint a reseller and they will register,” rewrite it. The reseller may sell. The reseller is not automatically the ARCSA titular. Mixing those roles is how you hand the license to the channel.

What ARCSA actually holds

ARCSA (Agencia Nacional de Regulación, Control y Vigilancia Sanitaria) is Ecuador’s sanitary authority for devices on the commercial track. The registro sanitario is the permit to manufacture, import, store, distribute, and promote the authorized configuration. Tecnovigilancia, renewals, and variations sit with the named holder — not with a U.S. complaint desk that “will translate later.”

That is a different file from a clinical investigation. Ethics in Ecuador sits with a CEISH (Comité de Ética de Investigación en Seres Humanos). ARCSA may also see a trial petition. Those clocks are a file problem on the FIH track. They are not a waiver of sanitary registration if you later want to sell the device in Ecuador. Do not clear investigational units on a commercial registro number, and do not tell the hospital that “we have a distributor, so ethics is optional.”

A 2025 PAHO-presented package of Ecuador clinical-research rules is not, by itself, fully in force. Do not put a PAHO slide on the Gantt as if it were the current ARCSA instruction. Confirm the instrument that is actually applied before you quote an Ecuador first-patient week.

Single-IoR is the design, not a preference

bioaccess®’s published IOR-versus-holder map treats Ecuador as a single-IoR model: the sanitary registration is bound to one locally registered Ecuadorian company. You can still have downstream commercial distributors. At the regulatory level there is one accountable party per registration.

Consequence:

• If the distributor is the ARCSA holder, they control market access. Transfer depends on their cooperation and on ARCSA’s transfer path — not on your U.S. termination clause.
• If a neutral Ecuadorian company holds the certificate, you can change the sales channel without restarting the sanitary file as a hostage negotiation.
• Import paperwork that names someone other than the authorized holder/importer pair is a customs problem, not a “broker will fix it” problem.

Argentina is the other strict single-IoR example in that same map (AAR under Disposición ANMAT N° 64/2025). Ecuador is not Argentina. Do not copy the ANMAT dossier onto ARCSA. Do use the same structural question: who owns the certificate when the distributor relationship breaks?

CE Mark is evidence, not the Ecuador permit

FDA clearance and CE marking help the technical story. They do not replace ARCSA registro for a commercial SKU. Build an Ecuadorian file: Spanish labeling and IFU aligned to the intended purpose you will sell, quality evidence ARCSA’s current instruction will demand, and a local party who can answer inspections and tecnovigilancia.

Certified Spanish translations belong in that file. They are not a courtesy to the distributor. Mixing the trial informed-consent language with the commercial IFU is how both tracks pick up labeling debt.

Holder, warehouse, and tecnovigilancia

Ecuador market access fails in operations more often than in the PDF. Lock four roles before you book a launch quarter:

1. Who is the Ecuadorian company on the registro. The locally registered entity ARCSA will treat as the sole holder under Resolución ARCSA-DE-2023-033-AKRG.
2. Who is the importer of record for commercial freight. In a single-IoR market that party is usually the same legal face, or an importer the holder has actually authorized — not a freight forwarder with a borrowed tax ID.
3. Who files tecnovigilancia. Adverse-event and field-safety reporting for registered devices is a sanitary duty of the holder, not a U.S. mailbox.
4. Who owns variations. Model adds, software version bumps, and sterile-barrier changes need an Ecuadorian variation path once registro exists. Quiet EU updates do not auto-propagate.

How this interacts with FIH in Ecuador

A clinical investigation in Ecuador and a commercial ARCSA registro are still different workstreams. CEISH review and any ARCSA trial petition do not issue a selling license. Do not put first-patient kits on a commercial registration that does not cover the investigational configuration. If you also plan Ecuadorian patients, keep a separate investigation importer and a separate accountability log.

bioaccess® already runs the ARCSA / CEISH trial file as FIH work. Market access is the other column. Do not merge them because one agency acronym appears in both sentences.

Where teams burn quarters

• Distributor as titular by default. Easy to sign. Hard to unwind in a single-IoR market.
• Treating 2025 PAHO-presented trial rules as the commercial clock. Trial rules, even when in force, do not replace registro. And those 2025 slides may not be the live instrument.
• One Spanish pack for CEISH and for ARCSA registro. Consent language is not the IFU. Split the translation job.

One-page Ecuador gate this week

• List every SKU you intend to sell in Ecuador in the next 24 months.
• Name the locally registered Ecuadorian company that will apply under Resolución ARCSA-DE-2023-033-AKRG.
• Name the commercial IOR, the tecnovigilancia owner, and the variation owner — three lines, three document IDs.
• Separate the FIH/EFS column if you also plan Ecuadorian patients. Different dossier, different importer.
• Do not quote a first-patient or registro clock from a PAHO presentation until you hold the instrument ARCSA is actually applying.

If those four owners cannot point to the same intended-purpose sentence in Spanish, you are not ready to quote Ecuadorian hospital revenue. For the all-in holder model across LATAM, see bioaccess® market access / LATAM Launch — Ecuador’s single-IoR rule is exactly why “distributor-only” plans break.